SCHEMBL17599362

SCHEMBL17599362

Cc1ccc(C#N)c(S(=O)(=O)Nc2ccc(-c3cccc(C(=O)O)c3)c3ccccc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
GAA P10253 1/20 0.46
G6PD P11413 1/20 0.46
MAP1LC3B Q9GZQ8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
SLC16A3 O15427 1/20 0.41
ACLY P53396 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
MCL1 Q07820 1/20 0.40
THRB P10828 1/20 0.40
SGK1 O00141 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
NPY2R P49146 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599337 0.85 PTK2B (0.50) KMT2AMEN1GAAG6PDMAP1LC3B
SCHEMBL17599376 0.82 FABP4 (0.56) KMT2AMEN1GAAG6PDMAP1LC3B
SCHEMBL17599312 0.81 KEAP1 (0.61) KMT2AMEN1GAAMCL1KDM4E
SCHEMBL17599330 0.79 WDR5 (0.47) KMT2AMEN1ACLYMCL1KDM4E
SCHEMBL17613351 0.79 KDM4E (0.38) KMT2AMEN1GAAALDH1A1HPGD
SCHEMBL17599351 0.78 KMT2A (0.45) KMT2AMEN1SLC16A3ACLYTDP1
SCHEMBL17599403 0.78 WDR5 (0.49) KMT2AMEN1L3MBTL1SLC16A3ACLY
SCHEMBL17599404 0.77 KMT2A (0.48) KMT2AMEN1GAAG6PDL3MBTL1
SCHEMBL17599371 0.77 KMT2A (0.51) KMT2AMEN1L3MBTL1SLC16A3ACLY
SCHEMBL17599329 0.77 KMT2A (0.55) KMT2AMEN1ACLYMCL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed